Effect of a New HA Filler in Correcting Nasolabial Fold
NCT ID: NCT06574750
Last Updated: 2024-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
74 participants
INTERVENTIONAL
2021-10-16
2023-05-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of Neuramis in Correction of Nasolabial Fold
NCT01585220
To Evaluate the Efficacy and Safety of Injection With HARA as Compared to Restylane® Lidocaine in Temporary Correction of Nasolabial Folds
NCT04224649
Efficacy and Safety Study of SkinPlus-Hyal® to Nasolabial Fold
NCT01940575
Evaluate the Safety and Effectiveness of Sodium Hyaluronate When Used for the Correction of Nasolabial Folds
NCT04569045
A Comparative Analysis of Two Hyaluronic Acid Fillers for Nasolabial Fold Correction
NCT06351293
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
New HA filler (Curea)
The left/right assignment was sealed in a nontransparent envelop.
CUREAⓇ (ARIBIO, Ltd., Seoul, Republic of Korea)
Hyaluronic acid filler injection were administered into the mid-dermis of the nasolabial fold.
Juvederm
The left/right assignment was sealed in a nontransparent envelop.
JuvedermⓇ (Q-Med AB, Uppsala, Sweden)
Hyaluronic acid filler injection were administered into the mid-dermis of the nasolabial fold.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CUREAⓇ (ARIBIO, Ltd., Seoul, Republic of Korea)
Hyaluronic acid filler injection were administered into the mid-dermis of the nasolabial fold.
JuvedermⓇ (Q-Med AB, Uppsala, Sweden)
Hyaluronic acid filler injection were administered into the mid-dermis of the nasolabial fold.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* participants who had used a local topical preparation (steroid and retinoid) within 2 weeks before the study
* participants who had undergone chemical peeling, laser procedures, or acne treatments within 4 months before the study
* participants who had been injected with other biomaterials, including HA within 6 months before the study.
30 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Bundang Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bo Ri Kim
Assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bo Ri Kim, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Bundang Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Bundang Hospital
Seongnam, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E-2105/684-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.